The FDA is reviewing drug data and company resubmissions, while also overseeing the functions of the U.S. Department of Health and Human Services.
Steady: 0 in the last 7 days
Updated oct 6
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is reviewing drug data and company resubmissions, while also overseeing the functions of the U.S. Department of Health and Human Services.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.Sub-event
FDA reviews drug data and company resubmissions under HHS oversight.1 source
Keep exploring
The entities involved
Related events
- The FDA requested additional clinical data from Unicycive Therapeutics.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA rejected a drug application due to inadequate data, with Frances Kelsey involved in the review.
- Both the FDA and European Medicines Agency must adopt evidence-based principles for drug regulation.
- Both the FDA and the European Medicines Agency govern drug approval processes.